hematology

Learn about anemia in C3 glomerulopathy (C3G), including causes, symptoms, diagnosis, and treatment options to manage fatigue and improve quality of life.

Scientific Reports, Published online: 21 August 2026; doi:10.1038/s41598-026-67218-1 Enhanced thrombin generation potential in male and female patients with Fabry disease: a single-center observational study

Pediatric acute myeloid leukemia (AML) is a severe hematological malignancy where allogeneic hematopoietic stem cell transplantation (allo-HSCT) serves as a critical, life-saving intervention.

Pediatric acute myeloid leukemia (AML) is a severe hematological malignancy where allogeneic hematopoietic stem cell transplantation (allo-HSCT) serves as a critical, life-saving intervention.

Thrombosis associated with HIF-PH inhibitor therapy has become a major concern. While elevated transferrin (Tf) levels were previously thought to be the cause, recent findings suggest that Tf may actually inhibit thrombus formation. I propose a new hypothesis based on my own theory.

Inherited bone marrow failure syndrome, or IBMFS, describes a group of disorders in which inherited genetic abnormalities impair the bone marrow's ability to produce sufficient healthy blood cells.

Platelet-activating antibodies against platelet factor 4 (PF4) cause highly prothrombotic disorders with reduced platelet counts. In heparin-induced thrombocytopenia (HIT), these antibodies bind PF4–heparin complexes, causing heparin-dependent platelet activation. Less common autoimmune and spontaneous HIT variants that are triggered by heparin and nonpharmacologic polyanions, respectively, have …

Adelaide University's Professor Tim Hughes is leading a major new research program to shape the future of chronic myeloid leukaemia (CML) therapy, aiming to take patients beyond lifelong treatment, into sustained treatment free remission.

Enrico M. Novelli, MD, MS, has been named Director of the University of Maryland School of Medicine (UMSOM) Program in Sickle Cell Disease and a Professor in the Department of Medicine, Division of Hematology/Oncology. An internationally recognized expert in sickle cell disease, he will treat patients at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC…

PurposeTo observe the efficacy and adverse reactions of eltrombopag combined with rhTPO in the treatment of lymphoma patients with chemotherapy - induced thrombocytopenia (CIT).MethodsA retrospective study was performed on the clinical data of 61 patients using eltrombopag (75 mg once a day), 99 patients using rhTPO (15,000 U once daily), and 50 patients using eltrombopag (75 mg once a day) combi…

Nature Communications, Published online: 25 July 2026; doi:10.1038/s41467-026-75344-7 Achieving sustained response remains a challenge for patients with difficult-to-treat immune thrombocytopenia (ITP). Here, the authors report that low-dose baricitinib plus danazol may be effective for patients with difficult-to-treat ITP with acceptable safety profiles.

In leukemia's most aggressive forms, the blood cell factories in our bone marrow falter. Instead of dividing and multiplying at their usual prolific pace, generating hundreds of billions of new cells daily, some precursor cells stall out at an immature stage.

Sickle cell disease causes premature aging of blood stem cells, which scientists may be able to address with a special class of drugs, according to a new study from St. Jude Children’s Research Hospital. Patients with sickle cell disease experience higher rates of blood stem cell dysfunction and blood cancers compared with their peers, though […]

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell that normally helps the body fight infections. When these cells become cancerous, they grow out of control inside the bone marrow and crowd out healthy blood cells. This can lead to bone pain, frequent infections, anemia, kidney problems, and […] The post Doctors update the warning signs for the most dangerous mu…

Hemophilia B is a rare X-linked congenital bleeding disorder characterized by a deficiency in coagulation factor IX (FIX). Standard management relies on exogenous factor replacement; however, the development of neutralizing alloantibodies (inhibitors) against infused clotting factor can significantly reduce therapeutic efficacy and complicate long-term management. Consequently, patients turn to b…

A new report in The Lancet Haematology, led by Cleveland Clinic hematologist Bethany Samuelson Bannow, M.D., outlines practical strategies to improve diagnosis, care and outcomes globally for women and girls with hematological conditions, such as bleeding disorders, heavy menstrual bleeding, postpartum hemorrhage, thrombosis and maternal hematologic complications.

A new report in The Lancet Haematology, led by Cleveland Clinic hematologist Bethany Samuelson Bannow, M.D., outlines practical strategies to improve diagnosis, care and outcomes globally for women and girls with hematological conditions, such as bleeding disorders, heavy menstrual bleeding, postpartum hemorrhage, thrombosis and maternal hematologic complications. The Commission on Global Female …

Oppezzo and colleagues report that therapeutically blocking telomeric DNA damage signaling reduces senescence and inflammation and restores hematopoietic function in telomerase-deficient and physiologically aged mice.

Myelodysplastic syndromes (MDS) are a group of hematopoietic disorders characterized by ineffective hematopoiesis, with manifestations of cytopenias in one, two, or three lineages.